Original article—liver, pancreas, and biliary tractValue of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease
Section snippets
Materials and Methods
The study protocol was approved by the local ethics committee. Patient groups included AMA-positive autoimmune hepatitis (AIH) (IAH-G criteria fulfilled, no histologic features of PBC, and AMA-positive by routine ELISA; stable over many years); PSC (endoscopic retrograde cholangiopancreatography [ERCP]/magnetic resonance cholangiopancreatography [MRCP] diagnostic for PSC, except in 3 patients who fulfilled histologic criteria for small duct PSC); undetermined cholangiopathy (elevated alkaline
Results
The patient population comprised 281 individuals for whom clinical and demographic data are summarized in Table 1.
Discussion
In the present study, which included a large cohort of patients with various chronic, presumed autoimmune cholestatic liver conditions, we analyzed the prevalence of 5 PBC-specific (conventional anti-M2 IgG, anti-MIT3 IgG and IgA, anti-gp210, anti-sp100) and 3 autoimmune liver disease–associated autoantibodies (anti-SLA, anti-chromatin, and anti-centromere) and assessed their potential role in the differential diagnosis of patients with chronic cholestasis caused by presumed “autoimmune”
References (23)
- et al.
Antinuclear antibodies specific for primary biliary cirrhosis
Autoimmun Rev
(2003) - et al.
Pathogenesis of primary biliary cirrhosis
Clin Liver Dis
(2003) - et al.
Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens
Hepatology
(2001) - et al.
Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis
Hepatology
(1996) - et al.
Detection of Gp210 autoantibodies in primary biliary cirrhosis using a recombinant protein containing the predominant autoepitope
Hepatology
(1995) - et al.
Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis
J Hepatol
(2005) - et al.
Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen
Lancet
(1987) - et al.
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis
Lancet
(2000) - et al.
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis
Am J Gastroenterol
(2003) - et al.
Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?
Clin Gastroenterol Hepatol
(2004)
Autoantibodies in the diagnosis and management of liver disease
J Clin Gastroenterol
Cited by (35)
Increased sensitivity of gp210 autoantibody detection using a newly designed gp210 antigen
2022, Journal of Immunological MethodsCitation Excerpt :The predominant epitope of gp210 was identified to be a stretch of 15 amino acid (AA) within the C-terminal of the protein, DRKASPPSGLWSPAY (gp210 peptide) (Nickowitz and Worman, 1993). Due to the advantage of epitope specificity and limited false positive reactions, gp210 Ab is currently detected using the gp210 peptide as the antigen in clinical laboratories by enzyme-linked immunosorbent assay (ELISA) (Nakamura et al., 2005; Bauer and Habior, 2007; Milkiewicz et al., 2009)(Boudet et al., 1991; Yu et al., 1996)(Boudet et al., 1991; Yu et al., 1996). However, weaker interactions of small peptide antigens with the polystyrene or bead surfaces could cause an insufficient coating of antigen, as well as limited space accessibility for the antibody (Boudet et al., 1991; Yu et al., 1996)(Boudet et al., 1991; Yu et al., 1996)(Boudet et al., 1991; Yu et al., 1996)(Boudet et al., 1991; Yu et al., 1996).
The evolving potential of precision medicine in the management of autoimmune liver disease
2021, Precision Medicine and Artificial Intelligence: The Perfect Fit for AutoimmunityS-adenosyl-L-methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S-glutathionylation processes in cholangiocytes
2020, Biochimica et Biophysica Acta - Molecular Basis of DiseaseCitation Excerpt :Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by autoimmune destruction of small and medium-size intrahepatic bile ducts, mostly affecting middle-aged women [1,2]. Highly specific anti-mitochondrial (AMA) antibodies are found in 90–95% of patients [3–5]. The major AMA targeted autoantigen in PBC is an E2 component of pyruvate dehydrogenase complex (PDC-E2), localized to the inner mitochondrial membrane, and its immunodominant epitope is associated with the lipoyl domain of the enzyme [6].
Autoimmune Hepatitis Overlap Syndromes and Liver Pathology
2017, Gastroenterology Clinics of North AmericaCitation Excerpt :The frequency of this overlap syndrome in a large cohort of patients with AIH is 11%.11 Enzyme immunoassays that are specific for PBC, including antibodies to gp210, sp100, or individual mitochondrial antigens, have been demonstrated in 35% of AMA-negative patients with cholestatic phenotypes, and they can support the diagnosis of AMA-negative PBC in some patients within this heterogeneous subgroup.58,59 The management of the overlap syndromes has not been established by controlled clinical trial.12
Assessment of health related quality of life in polish patients with primary biliary cirrhosis
2016, Clinics and Research in Hepatology and GastroenterologyCholestatic phenotypes of autoimmune hepatitis
2014, Clinical Gastroenterology and HepatologyCitation Excerpt :Each scoring system has been deficient in detecting cholestatic phenotypes of AIH, and liver tissue examination has been the most valuable diagnostic instrument when coupled with clinical judgment.33,34 Serologic tests also may be useful in clarifying the diagnosis, and enzyme immunoassays designed to detect antibodies against diverse PBC-specific antigens may characterize patients with AIH and otherwise unclassifiable cholestatic disease.35 Furthermore, the presence of concomitant AMA and antibodies to double-stranded DNA has distinguished patients with features of AIH and PBC.36
Conflicts of interest These authors disclose the following: Gary L. Norman and Zakera Shums are employees of INOVA Diagnostics, Inc. The remaining authors disclose no conflicts.
Funding E. Jenny Heathcote has received an unrestricted grant from Axcan-Pharma.